<DOC>
	<DOCNO>NCT00270270</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety epoetin alfa versus placebo AIDS patient treatment anemia result disease result zidovudine ( AZT ) treatment AIDS . Epoetin alfa genetically engineer protein stimulates red blood cell production .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Epoetin Alfa Versus Placebo Treatment Anemia AIDS ( Acquired Immunodeficiency Syndrome ) Patients With Anemia Caused Disease Zidovudine ( AZT ) Therapy</brief_title>
	<detailed_description>It estimate approximately 75 % 80 % patient AIDS experience anemia , cause AIDS therapy patient receive AIDS treatment ( example , zidovudine [ AZT ] ) . Anemia condition patient normal level hemoglobin , substance red blood cell carry oxygen part body . People severe anemia may experience fatigue shortness breath activity . Therefore , condition negative influence person 's quality life . Epoetin alfa , use treat anemia , genetically engineer form natural hormone , erythropoietin , stimulates red blood cell production . This randomized , double-blind , placebo-controlled study open-label follow-up period design evaluate safety effectiveness epoetin alfa treatment compare placebo treatment patient AIDS treat AZT . The study consist three period : screening period determine patient eligible study , double-blind period , open-label period . During double-blind period , patient randomly assign one two group receive either epoetin alfa ( 100 unit per kilogram ) placebo inject vein ( intravenously ) three time per week 12 week hematocrit reach 38 % 40 % . In open-label period , patient receive epoetin alfa inject skin ( subcutaneously ) 6 month dose need maintain hematocrit level 38 % 40 % . Effectiveness determine change hemoglobin , hematocrit , reticulocyte count ( laboratory test use evaluate severity anemia ) , transfusion requirement , patient 's quality life assessment . Safety assessment include incidence severity adverse event study , result clinical laboratory test ( hematology , biochemistry , urinalysis ) , measurement vital sign , electrocardiogram ( ECGs ) physical examination finding . The study hypothesis treatment anemia patient AIDS receive AZT therapy , epoetin alfa superior placebo , measure change hemoglobin , hematocrit , reticulocyte count , transfusion requirement , patient 's quality life . Double-blind period : epoetin alfa ( 100 unit per kilogram [ U/kg ] body weight ) placebo , inject intravenously three time week 12 week . Open-label period : epoetin alfa inject skin 6 month , dose adjustment range 0 1,500 U/kg need maintain hematocrit level 38 % 40 % .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Patients confirm diagnosis AIDS , hematocrit &lt; =30 % preferably dependent transfusion history least 15 % decrease hematocrit since begin AZT therapy , become dependent transfusion clinically stable least 1 month study entry female must least 1 year postmenopausal , surgically sterile , practice effective method birth control , negative pregnancy test study entry . Patients history primary blood disease clinically significant disease malfunction lung , heart , hormone , neurological , gastrointestinal , reproductive urinary system , cause AIDS infection uncontrolled high blood pressure anemia cause condition AIDS ( example , vitamin deficiency bleed gastrointestinal tract ) serum ferritin value &lt; 30 ng/mL iron/total ironbinding capacity ( Fe/TIBC ) ratio le 15 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>erythropoietin</keyword>
	<keyword>Anemia</keyword>
	<keyword>Quality Life</keyword>
	<keyword>epoetin alfa</keyword>
	<keyword>HIV</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>AIDS</keyword>
</DOC>